Fosun Pharma raises $512 million, while Dynasty Reit cancels IPO

The market remains challenging for new listings and both deals attract modest demand from international investors, with Fosun forced to reallocate shares to retail investors to make up for the lack of institutional interest.
<div style="text-align: left;"> Fosun's Shanghai headquarters </div>
<div style="text-align: left;"> Fosun's Shanghai headquarters </div>
October 25, 2012

Shanghai Fosun Pharmaceutical has raised HK$3.97 billion ($512 million) after pricing its Hong Kong initial public offering at the bottom of the indicated range.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media